Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Global, Double-Blind, Randomized, Placebo‑Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM)

Next Previous
Trial Profile

A Phase 3 Global, Double-Blind, Randomized, Placebo‑Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eplontersen (Primary)
  • Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CARDIO-TTRansform
  • Sponsors Ionis Pharmaceuticals

Most Recent Events

  • 24 Dec 2024 Planned End Date changed from 1 Nov 2025 to 1 Aug 2026.
  • 24 Dec 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Apr 2026.
  • 02 Sep 2024 Results(n=1432) measuring the change in amyloid burden (defined as % change in ECV from baseline) over time in patients receiving eplontersen versus placebo , presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top